

## NEWS RELEASE

**Aspect Imaging's  
M2™ 3D MR-based Histology Platform featured at  
30<sup>th</sup> Annual Meeting of the Japanese Society of Toxicological Pathology**

Results from revolutionary 3D MRI-based histology platform shows utility in  
complimenting multiple pre-clinical applications in toxicological pathology

TOKUSHIMA, Japan -- (January 31, 2014): Aspect Imaging, the world leading developer of compact high-performance MRI systems, is featuring its [M2™ 3D MR-based Histology platform](#) at the [30<sup>th</sup> Annual Meeting of the Japanese Society of Toxicological Pathology](#) in Tokushima, Japan in the commercial exhibits, in a new technology workshop and as part of the scientific sessions. The 30<sup>th</sup> Annual Meeting of the Japanese Society of Toxicological Pathology (JSTP) is being held from January 30 – 31<sup>st</sup>, 2014 at the Awagin Hall in the Tokushima Arts Foundation For Culture in Tokushima, Japan.

"We are excited to have our M2 3D MRI-based histology system profiled so significantly to the Japanese market at the JSTP conference in the scientific sessions as well as in a new technology scientific workshop", says Uri Rapoport, Aspect Imaging's Founder and CEO. "Our platform is a real revolution in instrumentation for the toxicological pathology field because MR-based imaging of fixed tissue specimens provides complimentary information to conventional histopathology, as numerous digital slices from any plane are acquired in an intact specimen. Moreover, non-destructive quantification of 3D structures allows specimens to be imaged and subsequently sectioned for conventional histopathology. With our platform, the application of 3D MRI-based histology is now a practical, affordable tool for use in drug development and safety assessment."

Studies showing the complimentary 3D *in vivo* and *ex vivo* results derived from the M2™ 3D MR-based histology system are featured in a scientific presentation at the conference: "**Detecting and Quantifying Liver Pathologies Using Compact, High-Resolution 3D MRI-Based Histology**", (Paper P-40) by Dr. Yael Schiffenbauer et al.

A dedicated workshop on new techniques was also held at the conference, titled "**Practical Applications of MRI Histology in Toxicologic Pathology**". In the workshop, Drs. Nyska, Maronpot and Schiffenbauer presented 13 complete toxicological models, where key models of disease were characterized using Aspect Imaging's compact 3D MRI-based histology system to show excellent concordance between *in vivo*, *ex vivo* and conventional H&E histology, in addition to the added information and insights derived from the 3D MR data sets. The complete presentation is available online ([Part I](#) and [Part II](#)).

In addition, the M2™ 3D MR-based Histology system was just featured in the recently published scientific paper by Nyska, A. et al., "[Histopathology of biodegradable polymers: challenges in interpretation and the use of a novel compact MRI for biocompatibility evaluation](#)" (Polym. Adv. Technol., doi: 10.1002/pat.3238, 2014). In the journal paper, the M2 is described as "a tool for assessing biocompatibility and efficacy of implanted biodegradable materials, since it allows for the longitudinal imaging and quantification of inflammation *in vivo* caused by the device implantation, and enabling general inspection of shape, location and integrity of the device *in vivo*."

The M2™ 3D MR-based Histology system will be on display in the exhibit booth of [Primetech Corporation](#), Aspect Imaging's Japanese distributor, in the Awagin Hall in the Tokushima Arts Foundation For Culture in Tokushima, Japan from January 30 – 31, 2014.

### **About Aspect Imaging:**

Aspect Imaging ([www.aspectimaging.com](http://www.aspectimaging.com)) is the world's leader in the design and development of high-performance compact MR imaging and NMR systems for pre-clinical, clinical and advanced industrial applications. In the [clinical market](#), Aspect Imaging has multiple clinical programs underway including its system to provide highly efficient just-in-place compact MRI for imaging of the wrist. The system allows clinicians to harness the power and insights of MRI but without the cost, complexity and technical burden of traditional MRI systems. In the pre-clinical research market, [the M-series of compact MRI systems](#), including the M3 and M10 systems enable a wide variety of *in vivo* applications and research models. Aspect Imaging also supplies its M2™ magnet, gradients and handling systems to Bruker for use in its leading [ICON™ compact MRI platform](#). Due to its high-performance M2 permanent magnet and suite of related products, the ICON enables academic researchers and pharmaceutical companies to harness the power and insights of MRI but without the cost, complexity and technical burden of traditional MRI systems. Pre-clinically, Aspect Imaging's M2 system is also used for providing [3D MR-based Histology](#) to complement and direct pathology and histology-based analysis, as well as providing the M2 platform to Mediso Medical Systems for use in its [nanoScan®](#) integrated PET/MRI and SPECT/MRI systems. Aspect Imaging's novel permanent magnets are also used in advanced industrial applications including rheology where its [FlowScan™](#) platform can operate in-line, on-line or near-line on large-scale production lines for food processing, consumer products, oil and gas, biofuels and other applications providing real-time, non-invasive and quantitative read-outs for process and quality control.

For further information, please contact:

**Robert Sandler**  
SVP, Marketing  
Aspect Imaging  
T. 416.274.8166  
E. [rsandler@aspectimaging.com](mailto:rsandler@aspectimaging.com)